Trifluoperazine

Name: Trifluoperazine
Brand: MedChemExpress
SKU: HY-B0532
Rating: 5.0 (9 reviews)

Cat. No.: HY-B0532 Purity: 99.87%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Trifluoperazine, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine is a potent α1-adrenergic receptor antagonist. Trifluoperazine is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine can be used for the research of schizophrenia. Trifluoperazine acts as a reversible inhibitor of influenza virus morphogenesis.

For research use only. We do not sell to patients.

Trifluoperazine Chemical Structure

CAS No. : 117-89-5

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Trifluoperazine:

Trifluoperazine dihydrochloride In-stock
Trifluoperazine-d₈ Get quote
Trifluoperazine dimaleate Get quote

9 Publications Citing Use of MCE Trifluoperazine

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Dopamine Receptor Isoform Specific Products:

View All Isoforms

Dopamine Receptor D₁ Receptor D₂ Receptor D₃ Receptor D₄ Receptor D₅ Receptor

View All Adrenergic Receptor Isoform Specific Products:

View All Isoforms

α adrenergic receptor β adrenergic receptor

View All CaMK Isoform Specific Products:

View All Isoforms

CaMK II CaMK III/eEF-2K CAMK IV PHK Trio DCAMKL

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
KG-1a	IC₅₀	4.58 μM Compound: TFP	Antiproliferative activity against human KG1a cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human KG1a cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 31541872]
MCF7	IC₅₀	11.33 μM Compound: TFP	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 31541872]
MDA-MB-231	IC₅₀	21.58 μM Compound: TFP	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 31541872]
NCI-H1650	GI₅₀	12.2 μM Compound: Trifluoperazine	Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26372073]
NIH-3T3-G185	IC₅₀	10.9 μM Compound: Trifluoperazine	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	6.3 μM Compound: Trifluoperazine	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	7.2 μM Compound: Trifluoperazine	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NSC	IC₅₀	10.1 μM Compound: TFP	Cytotoxicity against human NSC cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human NSC cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29614416]
Neutrophil	IC₅₀	11.9 μM Compound: Trifluoperazine	Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced lysozyme release Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced lysozyme release	[PMID: 19699097]
Neutrophil	IC₅₀	12.2 μM Compound: TFP	Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of beta-glucuronidase release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of beta-glucuronidase release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge	[PMID: 12662101]
Neutrophil	IC₅₀	12.5 μM Compound: Trifluoperazine	Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced beta-glucuronidase release Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced beta-glucuronidase release	[PMID: 19699097]
Neutrophil	IC₅₀	12.7 μM Compound: TFP	Inhibition of 5 ug/ml CB-stimulated Lysozyme release from rat neutrophils Inhibition of 5 ug/ml CB-stimulated Lysozyme release from rat neutrophils	[PMID: 17320246]
Neutrophil	IC₅₀	13.2 μM Compound: TFP	Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of lysozyme release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of lysozyme release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge	[PMID: 12662101]
Neutrophil	IC₅₀	13.2 μM Compound: TFP	Inhibition of 1 uM fMLP-stimulated beta-Glucuronidase release from rat neutrophils Inhibition of 1 uM fMLP-stimulated beta-Glucuronidase release from rat neutrophils	[PMID: 17320246]
Neutrophil	IC₅₀	2.7 μM Compound: TFP	Inhibition of PMA-induced superoxide formation in Sprague-Dawley rat neutrophil Inhibition of PMA-induced superoxide formation in Sprague-Dawley rat neutrophil	[PMID: 16510283]
Neutrophil	IC₅₀	6.6 μM Compound: TFP	Inhibition of fMLP-induced superoxide formation in Sprague-Dawley rat neutrophil Inhibition of fMLP-induced superoxide formation in Sprague-Dawley rat neutrophil	[PMID: 16510283]
SK-BR-3	IC₅₀	15.89 μM Compound: TFP	Antiproliferative activity against human SKBR3 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human SKBR3 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 31541872]
SUM-159-PT	IC₅₀	17.03 μM Compound: TFP	Antiproliferative activity against human SUM159 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human SUM159 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 31541872]
Sf9	IC₅₀	0.0005 M Compound: Trifluoperazine	Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells	[PMID: 9873605]
U-87MG ATCC	EC₅₀	13.5 μM Compound: TFP	Induction of intracellular Ca2+ level in human U87MG cells by Fura-2 AM dye-based assay Induction of intracellular Ca2+ level in human U87MG cells by Fura-2 AM dye-based assay	[PMID: 29614416]
U-87MG ATCC	IC₅₀	9.9 μM Compound: TFP	Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29614416]

In Vitro

Trifluoperazine is a long-established, widely used 'conventional' antipsychotic agent. Trifluoperazine has been an extensively studied drug molecule that has been used as a calmodulin inhibitor^[3]^[4].
Trifluoperazine acts as a reversible inhibitor of influenza virus morphogenesis, but not budding, by disturbing cellular CaM and/or CaM-dependent functions^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

407.50

Formula

C₂₁H₂₄F₃N₃S

CAS No.

117-89-5

Appearance

Solid

Color

Off-white to light yellow

SMILES

FC(C(C=C1N2CCCN3CCN(C)CC3)=CC=C1SC4=C2C=CC=C4)(F)F

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (306.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4540 mL	12.2699 mL	24.5399 mL
5 mM	0.4908 mL	2.4540 mL	4.9080 mL
10 mM	0.2454 mL	1.2270 mL	2.4540 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.87%

Select Batch:

Data Sheet (275 KB) SDS (252 KB)

COA (249 KB) HNMR (279 KB) RP-HPLC (223 KB) MS (69 KB)

Handling Instructions (2659 KB)

References

[1]. Huerta-Bahena J, Villalobos-Molina R, García-Sáinz JA. Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983;23(1):67-70. [Content Brief]

[2]. Santofimia-Castaño P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28. [Content Brief]

[3]. Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;2004(1):CD003545. [Content Brief]

[4]. Howland RH. Trifluoperazine: A Sprightly Old Drug. J Psychosoc Nurs Ment Health Serv. 2016;54(1):20-22. [Content Brief]

[5]. Ochiai H, et al. Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells. Antiviral Res. 1991;15(2):149-160. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4540 mL	12.2699 mL	24.5399 mL	61.3497 mL
	5 mM	0.4908 mL	2.4540 mL	4.9080 mL	12.2699 mL
	10 mM	0.2454 mL	1.2270 mL	2.4540 mL	6.1350 mL
	15 mM	0.1636 mL	0.8180 mL	1.6360 mL	4.0900 mL
	20 mM	0.1227 mL	0.6135 mL	1.2270 mL	3.0675 mL
	25 mM	0.0982 mL	0.4908 mL	0.9816 mL	2.4540 mL
	30 mM	0.0818 mL	0.4090 mL	0.8180 mL	2.0450 mL
	40 mM	0.0613 mL	0.3067 mL	0.6135 mL	1.5337 mL
	50 mM	0.0491 mL	0.2454 mL	0.4908 mL	1.2270 mL
	60 mM	0.0409 mL	0.2045 mL	0.4090 mL	1.0225 mL
	80 mM	0.0307 mL	0.1534 mL	0.3067 mL	0.7669 mL
	100 mM	0.0245 mL	0.1227 mL	0.2454 mL	0.6135 mL